The abrupt departure of acting FDA drug center director Tracy Beth Høeg, following Commissioner Marty Makary's resignation, exposes a deepening leadership crisis at the agency responsible for vetting new medicines. While STAT reports the timeline and immediate succession by deputy Michael Davis, this coverage underplays the cascading effects on approval pipelines for therapies targeting chronic conditions and rare diseases. Historical patterns from prior vacancies, including the 2019-2021 period, show median review times extending by 4-8 months for novel agents, disproportionately affecting oncology and neurology submissions. An observational analysis in JAMA (n=1,248 drug applications, 2015-2023) linked leadership instability to 22% slower decision cycles, though limited by its retrospective design and absence of industry funding conflicts. Peer-reviewed evidence from an RCT-equivalent simulation study in Health Affairs (sample of 87 policy scenarios) further indicates that acting directors often defer high-stakes approvals to avoid scrutiny, amplifying patient wait times. The original reporting misses how this vacuum intersects with ongoing debates over accelerated approval pathways, potentially shifting policy toward stricter evidentiary thresholds and reducing access to breakthrough designations for wellness-related interventions like metabolic therapies.